R&D | April 17, 2026
Revvity aims to accelerate breakthroughs in cancer research
Revvity is positioning its technologies as a connected engine for discovery
Revvity is positioning its technologies as a connected engine for discovery
Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
This marks a meaningful step in the company's continued expansion in the region
Subscribe To Our Newsletter & Stay Updated
